Macquarie Group
ITRM

Macquarie Group’s Iterum Therapeutics ITRM Stock Holding History

Macquarie Group’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-33
Closed -$3K – 1843
2018
Q4 		$3K Buy
+33
New +$3.12K ﹤0.01% 2155

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return
TAM
Tyers Asset Management Austin, Texas $3.02B AUM 5.29% 1-Year Est. Return

Macquarie Group's ITRM Position: Q1 2019 in Review

Macquarie Group sold out of Iterum Therapeutics (ITRM) in Q1 2019, closing a stake of 33 shares — an estimated $3K sold.

Macquarie Group first reported a position in ITRM in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 18 funds tracked by Wall St. Rank hold ITRM as of Q1 2019.

  • Macquarie Group reported no remaining Iterum Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 33 Iterum Therapeutics shares in Q1 2019, an estimated $3K.
  • Macquarie Group first reported a position in Iterum Therapeutics in Q4 2018 and held it in 1 quarter.
  • Macquarie Group's Iterum Therapeutics position peaked at $3K in Q4 2018.
  • 18 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.